Resistant Hypertension: A Real Entity Requiring Special Treatment?

Resistant Hypertension: A Real Entity Requiring Special Treatment?

Aug 01, 2016

Overview : The concept of resistant hypertension (RH) has received great attention in the past years, mainly as a possible target population for innovative therapeutic strategies. An increasing number of original articles and commentaries have focused on the clinical significance, prognosis and... more

Retraction of the Jikei Heart Study

Oct 21, 2013

Overview : In 2007, the Lancet published the results of the Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study (1). According to the authors, the addition of the angiotensin... more

Pulmonary arterial hypertension in patients treated by dasatinib

May 17, 2012

Overview : Background Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder. The prognosis of CML has been transformed by tyrosine kinase inhibitors (TKIs), such as dasatinib. Knowledge Gap Although TKIs are usually well tolerated, these agents are nonetheless characterized by systemic toxicity... more